Tokyo Tape
Sign in
← H.U. Group Holdings

Quarterly report · Q1

4544.TEDINET S100OZDP
Period2022-04-01 → 2022-06-30
Filed2022-08-12
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 47
MetricValuePeriodScopeSource row
Revenue¥65.3bn2022-04-01 → 2022-06-30Cons.Net sales
Revenue¥272.9bn2021-04-01 → 2022-03-31Cons.Net sales (5-year summary)
Revenue¥63.5bn2021-04-01 → 2021-06-30Cons.Net sales
Operating income¥8.6bn2022-04-01 → 2022-06-30Cons.Operating income
Operating income¥12.2bn2021-04-01 → 2021-06-30Cons.Operating income
Ordinary income¥8.5bn2022-04-01 → 2022-06-30Cons.Ordinary income
Ordinary income¥47.4bn2021-04-01 → 2022-03-31Cons.Ordinary income loss (5-year summary)
Ordinary income¥11.9bn2021-04-01 → 2021-06-30Cons.Ordinary income
Profit before tax¥8.1bn2022-04-01 → 2022-06-30Cons.Income before income taxes
Profit before tax¥11.4bn2021-04-01 → 2021-06-30Cons.Income before income taxes
Net income (owners)¥5.6bn2022-04-01 → 2022-06-30Cons.Profit loss attributable to owners of parent
Net income (owners)¥29.6bn2021-04-01 → 2022-03-31Cons.Profit loss attributable to owners of parent (5-year summary)
Net income (owners)¥8.3bn2021-04-01 → 2021-06-30Cons.Profit loss attributable to owners of parent
Net income¥5.6bn2022-04-01 → 2022-06-30Cons.Profit loss
Net income¥8.3bn2021-04-01 → 2021-06-30Cons.Profit loss
Total assets¥278.3bnat 2022-06-30Cons.Assets
Total assets¥286.6bnat 2022-03-31Cons.Assets
Total assets¥250.2bnat 2021-06-30Cons.Total assets (5-year summary)
Total liabilities¥132.3bnat 2022-06-30Cons.Liabilities
Total liabilities¥146.4bnat 2022-03-31Cons.Liabilities
Net assets / equity¥146.0bnat 2022-06-30Cons.Net assets
Net assets / equity¥140.2bnat 2022-03-31Cons.Net assets
Net assets / equity¥118.5bnat 2021-06-30Cons.Net assets (5-year summary)
Cash and deposits¥39.7bnat 2022-06-30Cons.Cash and deposits
Cash and deposits¥46.5bnat 2022-03-31Cons.Cash and deposits
Cash & equivalents¥39.7bnat 2022-06-30Cons.Cash and cash equivalents
Cash & equivalents¥46.5bnat 2022-03-31Cons.Cash and cash equivalents
Cash & equivalents¥37.3bnat 2021-06-30Cons.Cash and cash equivalents
Cash & equivalents¥43.0bnat 2021-03-31dCons.Cash and cash equivalents
Operating cash flow¥6.1bn2022-04-01 → 2022-06-30Cons.Net cash provided by used in operating activities
Operating cash flow¥55.2bn2021-04-01 → 2022-03-31Cons.Net cash provided by used in operating activities (5-year summary)
Operating cash flow¥5.6bn2021-04-01 → 2021-06-30Cons.Net cash provided by used in operating activities
Investing cash flow−¥7.3bn2022-04-01 → 2022-06-30Cons.Net cash provided by used in investment activities
Investing cash flow−¥30.9bn2021-04-01 → 2022-03-31Cons.Net cash provided by used in investing activities (5-year summary)
Investing cash flow−¥3.4bn2021-04-01 → 2021-06-30Cons.Net cash provided by used in investment activities
Financing cash flow−¥6.4bn2022-04-01 → 2022-06-30Cons.Net cash provided by used in financing activities
Financing cash flow−¥21.7bn2021-04-01 → 2022-03-31Cons.Net cash provided by used in financing activities (5-year summary)
Financing cash flow−¥8.0bn2021-04-01 → 2021-06-30Cons.Net cash provided by used in financing activities
EPS (basic)¥98.252022-04-01 → 2022-06-30Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥519.552021-04-01 → 2022-03-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥146.32021-04-01 → 2021-06-30Cons.Basic earnings loss per share (5-year summary)
EPS (diluted)¥98.242022-04-01 → 2022-06-30Cons.Diluted earnings per share (5-year summary)
EPS (diluted)¥519.422021-04-01 → 2022-03-31Cons.Diluted earnings per share (5-year summary)
EPS (diluted)¥146.232021-04-01 → 2021-06-30Cons.Diluted earnings per share (5-year summary)
Equity ratio52.4%at 2022-06-30Cons.Equity to asset ratio (5-year summary)
Equity ratio48.9%at 2022-03-31Cons.Equity to asset ratio (5-year summary)
Equity ratio47.3%at 2021-06-30Cons.Equity to asset ratio (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 38
SegmentItemPeriodValue
Reconciling Itemsreconcilingrevenue2022-04-01 → 2022-06-30−¥3.5bn
Reconciling Itemsreconcilingrevenue intersegment2022-04-01 → 2022-06-30−¥3.5bn
Reconciling Itemsreconcilingsegment profit2022-04-01 → 2022-06-30−¥607m
jpcrp040300-q1r_E00967-000Clinical Lab Testing Businessreportable segmentrevenue2022-04-01 → 2022-06-30¥43.4bn
jpcrp040300-q1r_E00967-000Clinical Lab Testing Businessreportable segmentrevenue external2022-04-01 → 2022-06-30¥43.4bn
jpcrp040300-q1r_E00967-000Clinical Lab Testing Businessreportable segmentrevenue intersegment2022-04-01 → 2022-06-30¥27m
jpcrp040300-q1r_E00967-000Clinical Lab Testing Businessreportable segmentsegment profit2022-04-01 → 2022-06-30¥1.7bn
jpcrp040300-q1r_E00967-000In Vitro Diagnostics Businessreportable segmentrevenue2022-04-01 → 2022-06-30¥18.5bn
jpcrp040300-q1r_E00967-000In Vitro Diagnostics Businessreportable segmentrevenue external2022-04-01 → 2022-06-30¥15.0bn
jpcrp040300-q1r_E00967-000In Vitro Diagnostics Businessreportable segmentrevenue intersegment2022-04-01 → 2022-06-30¥3.5bn
jpcrp040300-q1r_E00967-000In Vitro Diagnostics Businessreportable segmentsegment profit2022-04-01 → 2022-06-30¥7.0bn
jpcrp040300-q1r_E00967-000Sterilization And Related Servicesreportable segmentrevenue2022-04-01 → 2022-06-30¥7.0bn
jpcrp040300-q1r_E00967-000Sterilization And Related Servicesreportable segmentrevenue external2022-04-01 → 2022-06-30¥7.0bn
jpcrp040300-q1r_E00967-000Sterilization And Related Servicesreportable segmentrevenue intersegment2022-04-01 → 2022-06-30¥4m
jpcrp040300-q1r_E00967-000Sterilization And Related Servicesreportable segmentsegment profit2022-04-01 → 2022-06-30¥440m
—segment totalrevenue2022-04-01 → 2022-06-30¥68.8bn
—segment totalrevenue external2022-04-01 → 2022-06-30¥65.3bn
—segment totalrevenue intersegment2022-04-01 → 2022-06-30¥3.5bn
—segment totalsegment profit2022-04-01 → 2022-06-30¥9.2bn
Reconciling Itemsreconcilingrevenue2021-04-01 → 2021-06-30−¥2.0bn
Reconciling Itemsreconcilingrevenue intersegment2021-04-01 → 2021-06-30−¥2.0bn
Reconciling Itemsreconcilingsegment profit2021-04-01 → 2021-06-30−¥502m
jpcrp040300-q1r_E00967-000Clinical Lab Testing Businessreportable segmentrevenue2021-04-01 → 2021-06-30¥41.7bn
jpcrp040300-q1r_E00967-000Clinical Lab Testing Businessreportable segmentrevenue external2021-04-01 → 2021-06-30¥41.7bn
jpcrp040300-q1r_E00967-000Clinical Lab Testing Businessreportable segmentrevenue intersegment2021-04-01 → 2021-06-30¥14m
jpcrp040300-q1r_E00967-000Clinical Lab Testing Businessreportable segmentsegment profit2021-04-01 → 2021-06-30¥6.7bn
jpcrp040300-q1r_E00967-000In Vitro Diagnostics Businessreportable segmentrevenue2021-04-01 → 2021-06-30¥16.4bn
jpcrp040300-q1r_E00967-000In Vitro Diagnostics Businessreportable segmentrevenue external2021-04-01 → 2021-06-30¥14.4bn
jpcrp040300-q1r_E00967-000In Vitro Diagnostics Businessreportable segmentrevenue intersegment2021-04-01 → 2021-06-30¥1.9bn
jpcrp040300-q1r_E00967-000In Vitro Diagnostics Businessreportable segmentsegment profit2021-04-01 → 2021-06-30¥5.3bn
jpcrp040300-q1r_E00967-000Sterilization And Related Servicesreportable segmentrevenue2021-04-01 → 2021-06-30¥7.4bn
jpcrp040300-q1r_E00967-000Sterilization And Related Servicesreportable segmentrevenue external2021-04-01 → 2021-06-30¥7.4bn
jpcrp040300-q1r_E00967-000Sterilization And Related Servicesreportable segmentrevenue intersegment2021-04-01 → 2021-06-30¥5m
jpcrp040300-q1r_E00967-000Sterilization And Related Servicesreportable segmentsegment profit2021-04-01 → 2021-06-30¥821m
—segment totalrevenue2021-04-01 → 2021-06-30¥65.4bn
—segment totalrevenue external2021-04-01 → 2021-06-30¥63.5bn
—segment totalrevenue intersegment2021-04-01 → 2021-06-30¥2.0bn
—segment totalsegment profit2021-04-01 → 2021-06-30¥12.7bn

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 460
ItemContextValueUnit
Other noePrior1YTDDuration120000000JPY
Other noeCurrentYTDDuration70000000JPY
Non operating expensesPrior1YTDDuration921000000JPY
Non operating expensesCurrentYTDDuration933000000JPY
Ordinary incomePrior1YTDDuration11929000000JPY
Ordinary incomeCurrentYTDDuration8455000000JPY
Gain on sales of noncurrent assets eiPrior1YTDDuration5000000JPY
Gain on sales of noncurrent assets eiCurrentYTDDuration0JPY
Gain on reversal of subscription rights to shares eiPrior1YTDDuration16000000JPY
Gain on reversal of subscription rights to shares eiCurrentYTDDuration－JPY
Other eiPrior1YTDDuration48000000JPY
Other eiCurrentYTDDuration－JPY
Extraordinary incomePrior1YTDDuration69000000JPY
Extraordinary incomeCurrentYTDDuration0JPY
Loss on retirement of noncurrent assets elPrior1YTDDuration29000000JPY
Loss on retirement of noncurrent assets elCurrentYTDDuration14000000JPY
Loss on valuation of investments in capital elPrior1YTDDuration－JPY
Loss on valuation of investments in capital elCurrentYTDDuration149000000JPY
Loss on valuation of other investments elPrior1YTDDuration525000000JPY
Loss on valuation of other investments elCurrentYTDDuration67000000JPY
Other elPrior1YTDDuration28000000JPY
Other elCurrentYTDDuration94000000JPY
Extraordinary lossPrior1YTDDuration583000000JPY
Extraordinary lossCurrentYTDDuration326000000JPY
Income before income taxesPrior1YTDDuration11415000000JPY
Income before income taxesCurrentYTDDuration8128000000JPY
Income taxes currentPrior1YTDDuration1282000000JPY
Income taxes currentCurrentYTDDuration840000000JPY
Income taxes deferredPrior1YTDDuration1803000000JPY
Income taxes deferredCurrentYTDDuration1700000000JPY
Income taxesPrior1YTDDuration3085000000JPY
Income taxesCurrentYTDDuration2541000000JPY
Profit lossPrior1YTDDuration8329000000JPY
Profit lossCurrentYTDDuration5587000000JPY
Profit loss attributable to non controlling interestsPrior1YTDDuration-13000000JPY
Profit loss attributable to non controlling interestsCurrentYTDDuration－JPY
Profit loss attributable to owners of parentPrior1YTDDuration8343000000JPY
Profit loss attributable to owners of parentCurrentYTDDuration5587000000JPY
Profit lossPrior1YTDDuration8329000000JPY
Profit lossCurrentYTDDuration5587000000JPY
Valuation difference on available for sale securities net of tax ociPrior1YTDDuration4000000JPY
Valuation difference on available for sale securities net of tax ociCurrentYTDDuration-293000000JPY
Foreign currency translation adjustment net of tax ociPrior1YTDDuration163000000JPY
Foreign currency translation adjustment net of tax ociCurrentYTDDuration4074000000JPY
Remeasurements of defined benefit plans net of tax ociPrior1YTDDuration42000000JPY
Remeasurements of defined benefit plans net of tax ociCurrentYTDDuration51000000JPY
Other comprehensive incomePrior1YTDDuration210000000JPY
Other comprehensive incomeCurrentYTDDuration3832000000JPY
Comprehensive incomePrior1YTDDuration8540000000JPY
Comprehensive incomeCurrentYTDDuration9420000000JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 14 of 14 passed
balance sheet identityconsolidated 2022-03-31pass rounding
balance sheet identityconsolidated 2022-06-30pass rounding
dei present pass
period resolution pass
statement vs summary · net assetsconsolidated 2022-03-31pass
statement vs summary · net assetsconsolidated 2022-06-30pass
statement vs summary · net income attributable to parentconsolidated 2021-04-01/2021-06-30pass
statement vs summary · net income attributable to parentconsolidated 2022-04-01/2022-06-30pass
statement vs summary · operating cash flowconsolidated 2021-04-01/2021-06-30pass
statement vs summary · operating cash flowconsolidated 2022-04-01/2022-06-30pass
statement vs summary · revenueconsolidated 2021-04-01/2021-06-30pass
statement vs summary · revenueconsolidated 2022-04-01/2022-06-30pass
statement vs summary · total assetsconsolidated 2022-03-31pass
statement vs summary · total assetsconsolidated 2022-06-30pass